Renal Cancer - Results from #1700

cMET - a prognostic marker in papillary renal cell carcinoma? January 13, 2022

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. January 13, 2022

A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. January 13, 2022

Short-Term and Long-Term Renal Outcomes in Patients With Obesity After Minimally Invasive Versus Open Partial Nephrectomy for the Treatment of Renal Cancer: Retrospective Study. January 12, 2022

The renal clear cell carcinoma immune landscape. January 12, 2022

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. January 11, 2022

Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. January 11, 2022

Disparities in Cancer Specific and Overall Survival Outcomes in African Americans with Renal Cell Carcinoma: Analysis from the International Marker Consortium for Renal Cancer (INMARC). January 10, 2022

Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. January 10, 2022

Identification of adhesion-associated extracellular matrix component thrombospondin 3 as a prognostic signature for clear cell renal cell carcinoma. January 7, 2022

Integrative clinical and molecular characterization of translocation renal cell carcinoma. January 7, 2022

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. January 6, 2022

Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. January 6, 2022

Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss January 5, 2022

Expanding the limits of nephron-sparing surgery: Surgical technique and mid-term outcomes of purely off-clamp robotic partial nephrectomy for totally endophytic renal tumors. January 5, 2022

Clinical Trial Shows Stereotactic Radiation Extends Systemic Therapy and Slows Kidney Cancer Progression January 4, 2022

Computer Generated R.E.N.A.L. Nephrometry Scores Yield Comparable Predictive Results to that of Human-Expert Scores in Predicting Oncologic and Perioperative Outcomes. January 4, 2022

ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade. January 4, 2022

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. January 4, 2022

Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance). January 3, 2022

Page 86 of 457